Efficacy and Safety of Electroacupuncture in the Treatment of Esophageal Symptoms in Non-erosive Reflux Disease (NERD) Patients
Investigating the Efficacy and Safety of Electroacupuncture in the Treatment of Esophageal Symptoms in Non-erosive Reflux Disease (NERD) Patients: A Pilot, Randomized Double-blinded, Sham-controlled Trial
The goal of this clinical trial is to learn if acupuncture works to treat non-erosive reflux disease (NERD) patients. The main questions it aims to answer are:
- Electroacupuncture (EA) is superior to sham EA in terms of easing the symptom severity of NERD.
- Acupuncture is able to influence gastrointestinal function, autonomic regulation, and stress responses in NERD patients.
Participants will:
- Receive acupuncture treatment twice per week for 6 weeks.
- Leave plasma, serum, saliva, stool, and urine samples at baseline, mid-treatment, and end-of-treatment.
- Complete patient-reported-outcomes (PROs) at baseline, mid-treatment, and end-of-treatment
研究概览
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Linda LD Zhong, PhD
- 电话号码:+65 67911744
- 邮箱:linda.zhong@ntu.edu.sg
研究联系人备份
- 姓名:Huangyan Chen
- 电话号码:+65 97663672
- 邮箱:huangyan001@e.ntu.edu.sg
学习地点
-
-
-
Singapore、新加坡、S637551
- Nanyang Technological University, School of Biological Sciences
-
接触:
- Huangyan Chen
- 电话号码:+65 97663672
- 邮箱:huangyan001@e.ntu.edu.sg
-
接触:
- Linda LD Zhong, PhD
- 电话号码:+65 65921733
- 邮箱:linda.zhong@ntu.edu.sg
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Adults aged 21 to 75 years at the time of consent;
- Presence of heartburn, regurgitation or chest pain before screening with a frequency of at least twice a week;
- No evidence of esophageal mucosal injury on endoscopy within the past 5 years;
- GERD-Q score ≥8 (indicating active GERD symptoms);
- Ability and willingness to provide written informed consent to participate.
Exclusion Criteria:
-
Structural or organic gastrointestinal disease, including but not limited to:
- gastrointestinal malignancy,
- eosinophilic esophagitis,
- esophageal stricture, varices, or infections,
- active peptic ulcer disease,
- gastric or duodenal tumors;
-
Presence of alarming symptoms (e.g. severe dysphagia, hematemesis, unexplained weight loss, or hematochezia, etc.);
-
History of digestive tract surgery or esophageal interventions, including chemotherapy, radiotherapy, radiofrequency ablation, endoscopic mucosal resection, or cryotherapy;
-
Use of prohibited medical treatment:
- acupuncture treatment on the abdomen and chest within past 1 month,
- concomitant medication affecting gastrointestinal motility or visceral sensitivity (antidiarrheals, antidepressants, narcotic analgesics, anticholinergics, etc.),
- antibiotics, prebiotics, probiotics, or immunosuppressants within 1 month prior to screening;
-
Presence of an implanted cardiac pacemaker;
-
History of hypersensitivity to acupuncture, or needle phobia;
-
Severe psychiatric illness (e.g. schizophrenia, major depression, dementia), cognitive impairment, or other conditions likely to compromise adherence to study procedures;
-
Pregnant or breastfeeding;
-
Current participation in other clinical trials that could interfere with study outcomes.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Electroacupuncture (EA)
The WHO Standardized Acupuncture Points Location will be used to identify the location of these acupoints: ST36 Zusanli, PC6 Neiguan, CV12 Zhongwan, LR3 Taichong, SP4 Gongsun; and auxiliary acupoints added according to symptom severity: PC7 Daling, ST44 Neiting, EX-HN3 Yintang, ST37 Shangjuxu, SP6 Sanyinjiao, LU7 Lieque. After sterilizing the skin, needles of 0.25 mm in diameter and 25-40 mm in length will be inserted into the acupoints to a depth of 10-30 mm outward and upward slightly. Needles will be lifted, thrust, and twirled evenly 3 times to achieve "de-qi". Paired electrodes of the EA apparatus will be attached transversely to the acupoint respectively with a continuous wave of 2/100 Hz and a current intensity of 1-5 mA (preferably with the skin around the acupoints shivering mildly without pain) for 30 min. |
The acupuncture needles and related equipment will have already received approval for routine Traditional Chinese Medicine (TCM) clinical practice in Singapore. |
|
假比较器:Sham-electroacupuncture (SEA)
The sham electroacupuncture group (SEA) penetrates acupuncture on non-acupuncture points (1 B-cun away from the acupuncture point and meridian). The same type of acupuncture needles will be used for SEA with the exact skin sterilization method. Insertion depth will be approximately less than 10 mm. The electrostimulator will not be switched on for these patients. All needles will be removed after 30 min of needle retention. |
The acupuncture needles and related equipment will have already received approval for routine Traditional Chinese Medicine (TCM) clinical practice in Singapore. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Gastroesophageal Reflux Disease Questionnaire (GERDQ)
大体时间:From enrollment to the end of follow-up at 16 weeks
|
≥ 50% reduction in total GERD-Q score or normalization (<8) |
From enrollment to the end of follow-up at 16 weeks
|
|
Gastrointestinal Symptom Rating scale (GSRS)
大体时间:From enrollment to the end of follow-up at 16 weeks
|
≥ 0.5 point decrease in mean GSRS Reflux domain value |
From enrollment to the end of follow-up at 16 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Quality of Life in Reflux and Dyspepsia questionnaire (QOLRAD)
大体时间:From enrollment to the end of follow-up at 16 weeks
|
≥ 0.5 point improvement on the mean QOLRAD score |
From enrollment to the end of follow-up at 16 weeks
|
|
Euro QoL (EQ-5D-5L)
大体时间:From enrollment to the end of follow-up at 16 weeks
|
change in index utility |
From enrollment to the end of follow-up at 16 weeks
|
|
Hospital Anxiety and Depression Scale (HADS)
大体时间:From enrollment to the end of follow-up at 16 weeks
|
categorical shift from ≥ 11 to < 11 or ≥ 8 to < 8, or ≥ 1.5 point reduction per HADS-A and HADS-D subscale |
From enrollment to the end of follow-up at 16 weeks
|
|
Visceral Sensitivity Index (VSI)
大体时间:From enrollment to the end of follow-up at 16 weeks
|
≥ 15% reduction from baseline |
From enrollment to the end of follow-up at 16 weeks
|
|
Esophageal Hypervigilance and Anxiety Scale (EHAS) Short Form
大体时间:From enrollment to the end of follow-up at 16 weeks
|
≥ 15% reduction from baseline |
From enrollment to the end of follow-up at 16 weeks
|
|
Simplified Constitution of Chinese Medicine Questionnaire (CCMQ)
大体时间:At baseline
|
At baseline
|
|
|
Traditional Chinese medicine functional gastrointestinal disorders syndrome scale (TCM-FGID)
大体时间:From enrollment to the end of follow-up at 16 weeks
|
(Total syndrome score before treatment - Total syndrome score after treatment) / Total syndrome score before treatment × 100% |
From enrollment to the end of follow-up at 16 weeks
|
|
Bang's blinding index (BBI)
大体时间:End of first week and sixth week of intervention
|
End of first week and sixth week of intervention
|
|
|
James' blinding index (JBI)
大体时间:End of first week and sixth week of intervention
|
End of first week and sixth week of intervention
|
|
|
Patient's global impression of change (PGIC)
大体时间:From mid-treatment to the end of follow-up at 16 week
|
From mid-treatment to the end of follow-up at 16 week
|
|
|
Daily patient diary
大体时间:From enrollment to the end of follow-up at 16 weeks
|
From enrollment to the end of follow-up at 16 weeks
|
合作者和调查者
调查人员
- 首席研究员:Linda LD Zhong, PhD、Nanyang Technological University
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
IPD sharing will be available upon request.
IPD 共享时间框架
Data will become available within 7 years after completion of the clinical trial.
IPD 共享访问标准
Individual participant data (IPD) will be made available to qualified researchers upon request. To access the data, researchers must submit a formal request, which will be reviewed and approved by the data-sharing committee. Data access will be granted for research purposes only and will require adherence to data use agreements and ethics guidelines.
IPD 共享支持信息类型
- 研究方案
- 树液
- 国际碳纤维联合会
- 分析代码
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.